Conference
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Abstract
BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence. The analysis reported here, with an additional 6 months of follow-up, was designed to assess longer-term efficacy and safety of pembrolizumab versus placebo, as well as additional secondary and …
Authors
Powles T; Tomczak P; Park H; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang Y-H; Lee JL
Volume
23
Pagination
pp. 1133-1144
Publisher
Elsevier
Publication Date
September 2022
DOI
10.1016/s1470-2045(22)00487-9
Conference proceedings
The Lancet Oncology
Issue
9
ISSN
1470-2045